GLP‑1 weight‑loss drugs linked to joint, muscle and foot changes, prompting activity guidance

Orthopedic experts warn that patients using GLP‑1 medications such as Ozempic, Wegovy or Mounjaro may experience rapid weight loss that eases pressure on knees but can also lead to loss of lean muscle, bone density and joint stability. Post‑menopausal women and older adults are especially vulnerable to osteoporosis and fragility fractures, so clinicians advise adequate protein intake and resistance training to preserve muscular and skeletal health.

Doctors have also identified a pattern termed “Ozempic feet,” where rapid weight reduction makes the feet appear thinner, with sagging skin, prominent veins and reduced cushioning. Patients report discomfort, instability and pain, especially when more than 15‑20% of body weight is lost quickly. Recommendations include proper footwear, foot re‑measurement and protective padding, alongside the same protein‑rich diet and strength‑building exercises.

The UK Chief Medical Officers updated their Physical Activity Guidelines to stress the importance of strength and balance activities for anyone on GLP‑1 agonists. The guidance notes that any increase from inactivity—walking, stair climbing, light‑intensity tasks—confers health benefits and helps mitigate musculoskeletal risks associated with these drugs.